- Home
- OTLK
as 07-26-2024 4:00pm EST
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | ISELIN |
| Market Cap: | 178.6M | IPO Year: | 2016 |
| Target Price: | $46.43 | AVG Volume (30 days): | 221.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.00 - $34.80 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Outlook Therapeutics Inc. (OTLK)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Evanson Jeff | OTLK | CHIEF COMMERCIAL OFFICER | Mar 7 '24 | Buy | $0.42 | 62,484 | $26,243.28 | 808,459 | SEC Form 4 |
Latest Outlook Therapeutics Inc. News
OTLK Breaking Stock News: Dive into OTLK Ticker-Specific Updates for Smart Investing
MT Newswires
18 days ago
Outlook Therapeutics Receives UK Marketing Authorization for Eye Disease Drug
GlobeNewswire
18 days ago
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Simply Wall St.
a month ago
Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders are individual investors with 31% ownership, private equity firms own 31%
GlobeNewswire
a month ago
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
MT Newswires
2 months ago
Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD
GlobeNewswire
2 months ago
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Thomson Reuters StreetEvents
2 months ago
Q2 2024 Outlook Therapeutics Inc Earnings Call
GlobeNewswire
2 months ago
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
Compare OTLK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OTLK Outlook Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.